Overview

Study Using Eculizumab in Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients

Status:
Completed
Trial end date:
2006-01-01
Target enrollment:
Participant gender:
Summary
The primary objective is to evaluate the safety and efficacy of eculizumab in transfusion dependent patients with hemolytic PNH.
Phase:
Phase 3
Details
Lead Sponsor:
Alexion Pharmaceuticals
Treatments:
Eculizumab